Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
about
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphomaCandidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Specific Inhibition of β-Catenin in Jeko-1 Mantle Cell Lymphoma Cell Line Decreases Proliferation and Induces Apoptosis.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomesHigh incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survivalDiagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphomaGene mutations and actionable genetic lesions in mantle cell lymphoma.Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas - a single centre experience.Mantle cell lymphoma presenting as multiple lymphomatous polyposis of the gastrointestinal tract.Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment.ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel.Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randImpressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab.The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
P2860
Q26772907-E54B97FD-BB93-4513-9419-7D86E896E0F7Q26779612-B47D817B-D6CA-4A3F-949E-37DC54A0887AQ33671281-C769913D-5D0B-4FC2-A7FD-972626CFA2A8Q36010199-471C29C7-C933-4EA2-A72A-02CB49F602FDQ36278006-11ED1207-2ADD-4ED3-BC67-B40C7A079218Q36561781-1029E20C-54BC-4A04-B819-F7ED73CF26FBQ36756034-AE8E3E33-5A49-427D-A4E9-CDC9AF722FE6Q37544340-9F343344-0EAB-493E-BCDB-6D0B7985AEF9Q37629080-3C79C1EA-3AC4-4B77-8620-0DFD789B15DBQ37671462-F75BE95F-0CA4-41ED-BFF6-03B28C81B50DQ37683338-1BBE3006-1D34-4D92-9411-006F741C72FFQ38376021-DA561069-9B76-46E0-8C6F-35502A8A663EQ38538693-663EAF92-4D6E-48FD-BAE3-8E85DB02C982Q38612385-DD1C1C5C-C330-42F3-9AD1-CF00A7E7157CQ38768069-F602EE46-EEC0-4CA3-A4C9-3B427FC3DEC1Q38777496-CDD5FB94-E6C0-4E2C-AB07-DEF7D0310E9CQ39005626-22D60F7E-562A-40E7-AFAD-806EDCE53320Q39230986-7DE45E3A-A1BF-437E-ADF8-B39DB087D545Q39324849-9AA52AF3-590E-438E-AA7B-05BA6985D0DDQ39728290-7D6434BB-D676-4FAB-BF21-F5D707E292C1Q39788797-A50E4172-616C-4F36-B3FD-62B27924B403Q39914674-ADB4085B-1FF7-4FCF-8A85-356367C67B98Q40449915-754F4FAD-D394-4707-9803-6FB6D95DD2F3Q40494935-D9EEE09F-326F-4B5A-92E6-739BE14E0C43Q41416975-201B7EE8-776F-42F9-B82C-97D3286905D7Q42348448-B28F11DB-AEC7-4395-B022-3415F7FE3446Q42848307-0BED05CF-27EA-45CB-A631-86A6F7A818CEQ43296855-8AF465EE-F8EC-4828-866B-E38BBE1AA644Q46675870-86DE44E6-896E-49D0-8AEC-31555EBEC260Q47214441-3AFCA27A-C7DD-4522-84E5-8A03E82FEAF6Q47387312-13A518D0-465B-4B99-BC25-91B2BAF001B1Q48105468-6620EA94-0C46-4E45-9104-00C888228E94Q48206720-4CAC1214-FF59-44FC-A7B2-51F3A23475B3Q48238170-F59A862F-E0EF-4210-B050-F48000062884Q48335342-2A2B1AD9-D1AA-45F6-B231-1C4765A237EAQ49605090-4D1FDC6A-F606-4F18-A30C-72CE2507290CQ50025694-1F397E40-3C4C-446B-B1CD-4BD5B428F793Q51677133-21692DD6-0ED2-48B4-99D1-8BED20589B85Q52648382-39D5C3B3-CCCA-4FBB-999F-DD83CDC1133CQ53006177-34405F4C-575E-4E73-8D93-08C938B81C9B
P2860
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
description
im September 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 September 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2014
@uk
name
Newly diagnosed and relapsed m ...... nosis, treatment and follow-up
@en
Newly diagnosed and relapsed m ...... nosis, treatment and follow-up
@nl
type
label
Newly diagnosed and relapsed m ...... nosis, treatment and follow-up
@en
Newly diagnosed and relapsed m ...... nosis, treatment and follow-up
@nl
prefLabel
Newly diagnosed and relapsed m ...... nosis, treatment and follow-up
@en
Newly diagnosed and relapsed m ...... nosis, treatment and follow-up
@nl
P2093
P2860
P50
P356
P1433
P1476
Newly diagnosed and relapsed m ...... nosis, treatment and follow-up
@en
P2093
ESMO Guidelines Working Group
M Dreyling
O Shpilberg
S Le Gouill
P2860
P304
P356
10.1093/ANNONC/MDU264
P433
P478
25 Suppl 3
P577
2014-09-01T00:00:00Z